A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), [S. l.], v. 2, n. 5, 2009. DOI: 10.4081/hmr.v2i5.725. Disponível em: https://journals.pagepress.org/hmr/article/view/725. Acesso em: 20 jun. 2025.